|
Decision
Point 5
|
The PCP said he had heard that the FDA looks upon each LMWH as a unique drug with many unique properties. Is there any aspect in which the LMWHs are clearly similar?
a)
Efficacy
b) Molecular
weight
c)
Pharmacokinetics
d)
Production by fractionation of unfractionated
heparin
